A Single Center, Phase 1, Randomized, Open-Label Bioequivalence Trial in Healthy Volunteers Comparing ACP-011 Administered as a Single Dose via Syringe and Needle vs. Auto-Injector
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Sep 2018
At a glance
- Drugs ACP 001 (Primary)
- Indications Somatotropin deficiency
- Focus Pharmacokinetics
- Sponsors Ascendis Pharma
- 05 Sep 2018 Status changed to active, no longer recruiting.
- 05 Sep 2018 Planned End Date changed from 3 Jan 2018 to 15 Sep 2018.
- 25 Oct 2017 New trial record